1. Pink Sheet

The Implications Of The New EU HTA Regulation For Companies

Joint Clinical Assessments Will Become A Key Part Of The New Environment

 
• By Alexander Natz

Legal and industry expert Alexander Natz sets out key questions and answers to help companies prepare for new EU regulations on health technology assessments, one of the biggest developments to affect the pharmaceutical industry in over a decade.

Increased cooperation on HTA across the EU aims to help patients, payers and business • Source: Alamy

Regulation (EU) 2021/2282 on health technology assessment (HTA) is now in force and will bring important and wide-reaching changes that pharmaceutical companies need to understand.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Market Access